Company Announcements

Directorate Change

Source: RNS
RNS Number : 8400S
Bunzl PLC
19 July 2022

19 July 2022




Bunzl plc, the specialist international distribution and services Group, today announces the appointment of Dr. Pamela Kirby as a non-executive director and as a member of the Remuneration, Audit, Nomination and Board Sustainability Committees.


Pamela Kirby will join the Board and the aforesaid Committees with effect from 1 August 2022. She is presently a non-executive director of Reckitt Benckiser Group PLC and a member of the Supervisory Board of AkzoNobel N.V.


Pamela Kirby has significant knowledge and experience in global businesses, having worked in several international roles for over 30 years. She has held senior executive positions at AstraZeneca PLC and F. Hoffman-La Roche Ltd. and was formerly Chief Executive Officer of Quintiles Transnational Corporation. She was also previously a non-executive director of DCC plc, Hikma Pharmaceuticals PLC and Senior Independent Director of Victrex plc.


Commenting on the appointment, Peter Ventress, Chairman of Bunzl, said:


"I am delighted to welcome Pamela Kirby to Bunzl as a non-executive director. Through her executive and non-executive roles, she brings a wealth of international distribution, strategic and UK listed company experience to the Board and I am confident that she will enhance and strengthen the capabilities and diversity of the Board further."




Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Tel: +44 (0)20 7725 5000


Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200


Bunzl plc confirms that there are no other disclosures that need to be made under Listing Rule 9.6.13 in relation to Dr. Kirby's appointment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.